In the FAST trial, which enrolled patients with CLDN18.2 expression in ≥40% of tumor cells, the magnitude of the survival benefit was better in patients with CLDN18.2 expression in ≥70% of the tumor cells (median OS 16.5 vs. 8.9 months, HR 0.50, 95% CI 0.33–0.74; p < 0.0005) than in the overall population [45]. This evidence concerns the gene CLDN18 and neoplasm.